Background and objective: Parapneumonic effusion (PPE) is commonly caused by Gram-positive bacteria (GPB) and often presents with pleural loculation, which is characterized by overproduction of plasminogen activator inhibitor (PAI)-1. Lipoteichoic acid (LTA), a surface adhesion molecule of GPB, binds to the pleural mesothelium and triggers inflammation. However, the effects of LTA on PAI-1 expression in PPE and underlying mechanisms remain unclear. Methods: Thirty consecutive patients with PPE were enrolled, including uncomplicated culture negative (CN, n = 11), Gram-negative bacteria (GNB, n = 7) and GPB (n = 12) groups stratified by pleural fluid characteristics and bacteriology, and the effusion PAI-1 levels were measured. In addition, human pleural mesothelial cells (PMC) were treated with LTA and the expression of PAI-1 and activation of signalling pathways were assayed. Results: The median levels of PAI-1 were significantly higher in GPB (160.5 ng/mL) and GNB (117.0 ng/mL) groups than in the uncomplicated CN (58.0 ng/mL) group. In human PMC, LTA markedly upregulated PAI-1 mRNA and protein expression and enhanced elaboration of Toll-like receptor 2 (TLR2). Furthermore, LTA increased c-Jun N-terminal kinase (JNK) phosphorylation, induced activating transcription factor 2 (ATF2)/cJun nuclear translocation and activated PAI-1 promoter activity. Pretreatment with TLR2 siRNA significantly inhibited LTA-induced JNK phosphorylation and PAI-1 protein expression. Conclusion: Culture-positive PPE, especially that caused by GPB, has a significantly higher level of PAI-1 than uncomplicated CN PPE. LTA upregulates PAI-1 expression through activation of TLR2/JNK/activator protein 1 (AP-1) pathway in human PMC. Better understanding of the modulation of PAI-1 synthesis by LTA in PPE may provide potential therapies for infected pleural effusions.
INTRODUCTION
Parapneumonic effusion (PPE) is a common complication of pneumonia, characterized by the invasion of bacteria across the visceral pleura which incites a series of inflammatory responses leading to pleural exudates, empyema and fibrosis, and results in significant morbidity and mortality. 1 Pleural mesothelial cells (PMC) constitute a monolayer of cells covering the pleural surface and act as the initial defence against invading pathogens.
2 In response to infections, PMC elaborate plasminogen activator inhibitor (PAI)-1 to inactivate plasminogen activators and inhibit fibrinolysis, resulting in fibrin deposition, pleural loculation and fibrosis. 3, 4 Previous studies reported that PAI-1 level is significantly higher in complicated PPE than in uncomplicated PPE and is associated with residual pleural thickening (RPT).
5,6

SUMMARY AT A GLANCE
In Gram-positive parapneumonic effusions, lipoteichoic acid (LTA) upregulates plasminogen activator inhibitor-1 (PAI-1) expression through activation of Toll-like receptor 2 (TLR2)/c-Jun N-terminal kinase (JNK)/activator protein 1 (AP-1) pathway in human pleural mesothelial cells. Improved understanding of the modulation of PAI-1 synthesis by LTA may provide potential therapies for pleural effusions caused by infection.
Gram-positive bacteria (GPB), including streptococcal or staphylococcal species, are a common cause of PPE. 1 Lipoteichoic acid (LTA), the major cell wall component of GPB, binds to target cells to induce inflammation and coagulation and is considered as a virulent factor essential for GPB infections and postinfectious sequelae. 7, 8 LTA was reported to induce pleural inflammation and fibrosis and has been used as an effective pleurodesis agent for malignant pleural effusions. 9 Moreover, postinfection pleurodesis developed in some patients with malignant pleural effusions drained using indwelling pleural catheters, especially those infected with staphylococci. 10 A previous study showed that bronchial instillation of LTA inhibited lung fibrinolysis evidenced by markedly elevated PAI-1 levels in bronchoalveolar fluid, 11 implying that LTA may disrupt fibrinolysis through induction of PAI-1. However, to our knowledge, the implication of LTA in PAI-1 production in the pleural space has never been investigated. The present study aims to survey the PAI-1 levels in GPB PPE and to elucidate the effects of LTA on PAI-1 expression in human PMC and the underlying mechanisms.
METHODS
Patient selection
Consecutive patients with community-acquired pneumonia and pleural effusion admitted to Taipei Medical University Hospital were eligible and included if the PPE was an exudate. 12 Ethics approval (CRC-05-11-01) was conferred by the Institutional Review Board of Taipei Medical University Hospital (Taipei, Taiwan). All patients provided written informed consent prior to entering the study.
Exclusion criteria included a history of invasive pleural procedures, recent severe trauma, haemorrhage or stroke; bleeding diathesis or anticoagulant therapy.
Within 24 h after hospitalization, 50 mL of pleural fluid was aspirated with the guidance of chest ultrasonography. When pleural effusion was multiloculated, fluid was acquired from the largest locule. Pleural fluid analyses were performed routinely and standard aerobic and anaerobic culture bottles were inoculated with 5 mL of pleural fluid each. Additionally, two pleural fluid specimens were injected into paired blood culture bottles to increase the growth rate. 13 All PPE patients were categorized later based on the results of microbiological cultures as GPB, Gram-negative bacteria (GNB) or culture-negative (CN) groups. The CN effusion was defined as a PPE with negative smear and no growth of bacteria in all standard and blood culture bottles for 7 days.
Measurement of effusion PAI-1
Commercial enzyme-linked immunosorbent assay kits were used to measure effusion levels of PAI-1 (American Diagnostica, Greenwich, CT, USA) as previously described. 5, 6 Statistical analysis Quantitative data are presented as mean (SEM) or median (range). Comparisons of continuous data were made using one-way analysis of variance or KruskalWallis test among three groups, and unpaired t-test or Mann-Whitney U-test between two groups, where appropriate. P < 0.05 was considered statistically significant.
Other methods are included in Appendix S1 (Supplementary Information). 0.094 *P < 0.05 compared with the CN group; **P < 0.01 compared with the CN group; ***P < 0.001 compared with the CN group. † Data expressed as median (range). ‡ For comparisons among three groups. CN, culture negative; GNB, Gram-negative bacteria; GPB, Gram-positive bacteria; LDH, lactate dehydrogenase.
RESULTS
Pleural fluid characteristics and PAI-1 levels among GPB, GNB and CN groups Thirty consecutive patients with documented pneumonia and PPE were enrolled (Table 1) , including 16 men with an age range from 42 to 80 years (mean age: 64 years). Twelve patients had GPB (Staphylococcus aureus in 9 and Streptococcus pneumoniae in 3), 7 had GNB (Klebsiella pneumoniae in 3, Pseudomonas aeruginosa in 3 and Escherichia coli in 1) and 11 had no growth in their pleural fluid culture; all patients Figure 1 Gram-positive parapneumonic effusions have significantly higher PAI-1 level than CN effusions (A). LTA upregulates PAI-1 expression in human PMC (B, C). MeT-5A PMC were treated with LTA (0.5-5 μg/mL) for 24 h (B) or stimulated with various concentrations of LTA for 6 h (C), and PAI-1 protein and mRNA expression were analysed by Western blot and semiquantitative reverse transcriptase PCR, respectively. Data are shown as mean AE SEM of five independent experiments. *P < 0.05 and ***P < 0.001 compared with CN group; # P < 0.05 and ### P < 0.001 compared with the resting group. CN, culture negative (n = 11); GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GNB, Gram-negative bacteria (n = 7); GPB, Gram-positive bacteria (n = 12); LTA, lipoteichoic acid; PAI, plasminogen activator inhibitor; PMC, pleural mesothelial cell. MeT-5A cells were treated with LTA (1 μg/mL) for the indicated times. JNK expression was analysed by Western blotting with antibodies specific for phosphorylated or total proteins. Data are shown as mean AE SEM of four independent experiments. ***P < 0.001, # P < 0.05, finished 6 months of follow-up from January 2011 through December 2014. Pleural fluid characteristics demonstrated that, compared with GPB and GNB groups, all patients in the CN group presented with uncomplicated PPE. 12 Patients in the GPB group had significantly lower levels of effusion pH and glucose and higher values of protein, lactate dehydrogenase and leucocyte count than did the CN group. Additionally, there were significant differences in pleural fluid pH values between the GNB and CN groups ( Table 1) .
As shown in Figure 1A , the median levels of effusion PAI-1 were significantly higher in GPB (160.5 ng/mL, range: 102.1-350.0 ng/mL) and GNB (117.0 ng/mL, range: 63.0-258.0 ng/mL) groups compared with CN (58.0 ng/mL, range: 2.4-98.7 ng/mL) group (GPB vs CN, P < 0.001; GNB vs CN, P < 0.05), although the PAI-1 values were not statistically different between GPB and GNB groups. Subsequently, we set out to explore how GPB induced PAI-1 production in PPE.
LTA upregulates PAI-1 expression in human PMC
To verify the effect of GPB on PAI-1 expression, human PMC were treated with 0.5, 1 and 5 μg/mL of LTA for 24 h. A concentration of 1 μg/mL LTA significantly increased PAI-1 protein expression in MeT-5A cells compared with the resting condition (Fig. 1B) . To further investigate whether the increase in PAI-1 protein expression after LTA stimulation resulted from the induction of PAI-1 mRNA expression, reverse transcriptase PCR analysis was performed. After treatment with LTA (1 μg/mL) for 6 h, MeT-5A cells had a significant increase in PAI-1 mRNA expression (Fig. 1C) .
LTA enhances TLR2 expression in human PMC
Toll-like receptors (TLR) are known to recognize microbial bacteria components and initiate host defensive responses. 14 We examined the basal expression of TLR and whether LTA enhances TLR expression in human PMC. In Figure 2A , administration of LTA 1 μg/ mL significantly increased TLR2 expression in human PMC within 3 h compared with the basal status. However, TLR4 expression did not change substantially (Fig. S1, Supplementary Information) .
LTA activates phosphorylation of JNK in human PMC
Consequently, we used specific pharmacological inhibitors against nuclear factor kappa-B (NF-κB), phosphatidylinositol 3-kinase/AKT (PI3K/AKT) or mitogen-activated protein kinase (MAPK) to examine downstream signalling pathways of TLR that lead to PAI-1 production. Pretreatment with c-Jun N-terminal kinase (JNK) inhibitor (SP600125, 10 μmol/L) markedly attenuated the PAI-1 protein expression induced by LTA. In contrast, other signal inhibitors did not alter LTA-induced PAI-1 protein expression (Fig. S2, Supplementary Information) . Consistently, LTA significantly induced phosphorylation of JNK in a time-dependent manner with a maximal response occurring at 30 min compared with the resting condition (Fig. 2B) .
LTA activates ATF2/c-Jun nuclear translocation and PAI-1 promoter activity
Transcription factor activator protein 1 (AP-1) has been considered an essential regulator of fibrogenesis associated with inflammation. 15 We examined whether activation and translocation of AP-1 constituent proteins (activating transcription factor 2 (ATF2) and c-Jun) were required for LTA-induced PAI-1 expression in human PMC. As shown in Figure 3A , B, as compared with the resting condition, LTA significantly induced translocation of ATF2 and c-Jun into nucleus with a maximal response occurring at 30 min. Moreover, it has been reported that PAI-1 promoter contains AP-1-binding site that is important for initiation of PAI-1 gene expression. 16 We used a luciferase reporter assay to test whether PAI-1 gene transcription was triggered by LTA in human PMC. The result showed that LTA significantly increased PAI-1 promoter activity in a dose-dependent manner (Fig. 3C) .
LTA activates TLR2/JNK signalling to induce PAI-1 expression
Next, we used siRNA against TLR2 to verify whether TLR2/JNK signalling is implicated in LTA-induced PAI-1 expression in human PMC. Initially, the knockdown efficiency of siRNA was demonstrated as a significant decrease of TLR2 protein expression in human PMC transfected with TLR2 siRNA compared to those transfected with scrambled siRNA (Fig. 4A) . Pretreatment with TLR2 siRNA substantially reduced JNK phosphorylation and PAI-1 expression at 30 min and 6 h following LTA administration, respectively (Fig. 4B,C) , suggesting that TLR2 serves as the chief receptor for LTA to trigger JNK activation and PAI-1 expression in human PMC.
DISCUSSION
The present study demonstrated that culture-positive PPE, especially that caused by GPB, has significantly higher level of PAI-1 than uncomplicated CN PPE. The in vitro experiments showed that LTA markedly induced PAI-1 production and enhanced TLR2 expression in human PMC. Moreover, LTA significantly increased JNK phosphorylation, ATF2/c-Jun translocation and PAI-1 promoter activity, and TLR2 gene silencing substantially attenuated all these effects. This is the first study to signify the raised PAI-1 level in GPB PPE and to explore the molecular mechanisms of PAI-1 expression regulated by LTA in PPE.
Previous studies showed that PAI-1 concentrations are significantly higher in complicated PPE than in uncomplicated PPE, and substantially increased in PPE with RPT than those without, 5, 6 indicating that PAI-1 affects clinical outcome and is implicated in fibrotic sequel of PPE. Our results further demonstrated that PAI-1 level was substantially higher in culture-positive PPE, either GPB or GNB, than CN PPE. However, the limitation is that all the CN effusions included were uncomplicated PPE while the low pH but CN group was not represented in this data. Further study on CN complicated PPE is needed to verify that bacteria invade the visceral pleura and induce PAI-1 production in the pleural space. 1, 17 Moreover, the current study revealed, although the case number is too limited to reach a statistical significance, GPB pleural infection had a trend towards greater PAI-1 level than those caused by GNB, suggesting that LTA may play a key role in regulation of PAI-1 production in PPE.
Therefore, it is reasonable to assume that the elevated PAI-1 in PPE was elaborated by PMC upon stimulation by invading bacteria, especially GPB, and this merits further study of the underlying mechanism. In vitro, we demonstrated that LTA upregulated PAI-1 synthesis through increasing both mRNA and protein levels in human PMC, in keeping with the previous human study that bronchoscopic instillation of LTA substantially raised PAI-1 levels in bronchoalveolar fluids.
11 Moreover, another in vivo study demonstrated that after bronchial administration of LTA, bronchoalveolar PAI-1 levels were significantly elevated in wildtype mice. 18 Furthermore, the inducing effect of LTA on PAI-1 expression was markedly abrogated in TLR2-or TLR4-knockout mice, 18 implying that LTA may increase PAI-1 via a TLR-dependent pathway in Grampositive pneumonia. These findings suggested that LTA modulates fibrinolytic activity by increasing PAI-1 expression, possibly through TLR pathway activation.
TLR2 and TLR4 are important members of the TLR family whose roles in recognizing bacteria components and initiating inflammation are well defined, including modulation of gene expression and cellular function upon simulation by LTA or lipopolysaccharide (LPS). 14, 19, 20 A prior report showed that PMC, on exposure to staphylococcal peptidoglycan, upregulated TLR2 expression to trigger innate immune responses. 21 Our previous study demonstrated that Mycobacterium tuberculosis enhanced the expression of both TLR2 and TLR4 in PMC, but stimulated tumour necrosis factor (TNF)-α synthesis only via TLR2 activation. 22 In parallel, the current data revealed that TLR2 expression, but not TLR4, was enhanced significantly in PMC upon LTA treatment, implicating that GPB possibly activates TLR2 in pleural mesothelium in the process of pleural infection.
As for the downstream signalling, it has been reported that LTA stimulates human peripheral blood monocytes to produce TNF-α via activation of the NF-κB pathway. 19 Our previous study demonstrated that M. tuberculosis triggered TLR2/extracellular signalregulated kinase (ERK) signalling to induce TNF-α synthesis in human PMC. 22 In contrast, the current study revealed that JNK, but not NF-κB nor ERK, actively mediated LTA-induced PAI-1 production in human PMC. In addition, LTA activated the transcription factor AP-1 (ATF2/c-Jun), and subsequently increased PAI-1 promoter activity. Moreover, both JNK phosphorylation and PAI-1 expression induced by LTA were markedly attenuated by TLR2 silencing. Altogether, these results suggest that LTA upregulates PAI-1 expression in human PMC through activation of TLR2/JNK/AP-1 pathway. As our previous studies and the current data have signified that JNK/AP-1 signalling plays an essential regulator of gene expression implicated in PMC-orchestrated inflammation and fibrosis, 15, 23 it is warranted to employ JNK or AP-1 inhibition as a treatment strategy for PAI-1-associated pleural diseases. Systemic inhibition of JNK activation has been shown to decrease PAI-1 expression in the lungs of mice after LPS exposure, 24 and clinical trials using JNK inhibitors are ongoing for various inflammatory diseases. 25 Therefore, further studies targeting JNK or AP-1 as well as PAI-1 expression in pleural mesothelium are needed for developing novel agents for treatment of pleural infection.
In conclusion, culture-positive PPE, especially that caused by GPB, has significantly higher levels of PAI-1 than uncomplicated CN PPE. LTA upregulates PAI-1 expression through activation of TLR2/JNK/AP-1 pathway in human PMC (Fig. 5) . Improved understanding of PAI-1 synthesis by LTA in PPE may provide potential therapies for pleural effusions caused by infection.
